Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial

Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(1):213-226. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0640

View: 969 Download: 129

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):131-146. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0451

View: 1069 Download: 162

Reply to Correspondence

Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”

Pin-Nan Cheng, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(4):1031-1032. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0228

View: 1506 Download: 56

Original Article

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study

Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon

Clin Mol Hepatol. 2024;30(3):500-514. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0055

View: 2997 Download: 177 Web of Science: 2 Crossref: 3

Correspondence

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply

Hyeyeon Hong, Jonggi Choi

Clin Mol Hepatol. 2024;30(2):272-273. Published online February 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0123

View: 2276 Download: 83 Web of Science: 1 Crossref: 1

Original Article

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi

Clin Mol Hepatol. 2024;30(1):49-63. Published online November 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0328

View: 3576 Download: 239 Web of Science: 7 Crossref: 8

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 6319 Download: 302 Web of Science: 31 Crossref: 30

Editorial

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Hung-Yao Lin, Tai-Chung Tseng

Clin Mol Hepatol. 2022;28(2):181-182. Published online February 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0028

View: 5142 Download: 124 Web of Science: 5 Crossref: 4

Review

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim

Clin Mol Hepatol. 2021;27(3):402-412. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0179

View: 7119 Download: 273 Web of Science: 35 Crossref: 33

Original Article

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn

Clin Mol Hepatol. 2020;26(3):352-363. Published online May 28, 2020

DOI: https://doi.org/10.3350/cmh.2019.0044n

View: 5756 Download: 194 Web of Science: 6 Crossref: 8

Editorial

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0099

View: 5803 Download: 131 Crossref: 2

Review

Unmet need in chronic hepatitis B management

Lilian Yan Liang, Grace Lai-Hung Wong

Clin Mol Hepatol. 2019;25(2):172-180. Published online February 12, 2019

DOI: https://doi.org/10.3350/cmh.2018.0106

View: 10344 Download: 402 Web of Science: 44 Crossref: 46

Original Article

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin

Clin Mol Hepatol. 2017;23(3):230-238. Published online June 30, 2017

DOI: https://doi.org/10.3350/cmh.2017.0003

View: 10282 Download: 167 Web of Science: 12 Crossref: 14

Editorial

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(3):219-221. Published online September 19, 2017

DOI: https://doi.org/10.3350/cmh.2017.0045

View: 8312 Download: 155 Web of Science: 1 Crossref: 2

Original Article

Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B

Hee Yeon Seo, Han Ah Lee, Soon Young Ko, Joon Ho Wang, Jeong Han Kim, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2017;23(2):154-159. Published online May 8, 2017

DOI: https://doi.org/10.3350/cmh.2016.0067

View: 8031 Download: 178 Web of Science: 8 Crossref: 8

Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients

Goh Eun Chung, Eun Ju Cho, Jeong-Hoon Lee, Jeong-ju Yoo, Minjong Lee, Yuri Cho, Dong Hyeon Lee, Hwi Young Kim, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim

Clin Mol Hepatol. 2017;23(1):66-73. Published online February 14, 2017

DOI: https://doi.org/10.3350/cmh.2016.0060

View: 10771 Download: 168 Web of Science: 12 Crossref: 11

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)

Hye Won Lee, Jun Yong Park, Beom Kyung Kim, Moon Young Kim, Jung Il Lee, Young Suk Kim, Ki Tae Yoon, Kwang-Hyub Han, Sang Hoon Ahn

Clin Mol Hepatol. 2016;22(4):443-449. Published online November 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0037

View: 10527 Download: 159 Web of Science: 10 Crossref: 8

Editorial

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song

Clin Mol Hepatol. 2016;22(4):439-442. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0108

View: 8214 Download: 112 Web of Science: 1 Crossref: 1

Case Report

Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases

Hyeki Cho, Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Kook-Hwan Oh, Kyoungbun Lee, Syifa Mustika, Jung-Hwan Yoon, Yoon Jun Kim

Clin Mol Hepatol. 2016;22(2):286-291. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2015.0066

View: 11186 Download: 175 Web of Science: 11 Crossref: 13

Original Article

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy

Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon

Clin Mol Hepatol. 2016;22(2):241-249. Published online June 15, 2016

DOI: https://doi.org/10.3350/cmh.2015.0053

View: 10494 Download: 140 Web of Science: 4 Crossref: 4

Editorial

Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?

Hyung Joon Yim

Clin Mol Hepatol. 2016;22(2):238-240. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0103

View: 8913 Download: 97 Web of Science: 1 Crossref: 1

Original Article

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B

Chan Ho Park, Seok Won Jung, Jung Woo Shin, Mi Ae Bae, Yoon Im Lee, Yong Tae Park, Hwa Sik Chung, Neung Hwa Park

Clin Mol Hepatol. 2016;22(1):152-159. Published online March 28, 2016

DOI: https://doi.org/10.3350/cmh.2016.22.1.152

View: 10027 Download: 96

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy

Jung Gil Park, Soo Young Park

Clin Mol Hepatol. 2015;21(3):242-248. Published online September 30, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.3.242

View: 8813 Download: 88 Web of Science: 5 Crossref: 4

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients

Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa

Clin Mol Hepatol. 2015;21(1):41-48. Published online March 25, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.1.41

View: 9175 Download: 86 Web of Science: 15 Crossref: 12

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort

Sung Soo Ahn, Young Eun Chon, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park

Clin Mol Hepatol. 2014;20(3):261-266. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.261

View: 10089 Download: 79 Web of Science: 13 Crossref: 10

Correspondence

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Received February 3, 2025 Accepted February 12, 2025

DOI: https://doi.org/10.3350/cmh.2025.0121 [Accepted]

View: 4 Download: 0

1 |

Viewed By 6278	MAFLD: How is it different from NAFLD?
Viewed By 5057	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4861	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3501	Gut microbiome and metabolome signatures in liver cirrhosis-related complications
Viewed By 3119	Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Cited By 287	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 239	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 161	MAFLD: How is it different from NAFLD?
Cited By 85	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 81	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search